TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Recognition of unique pCLE images for endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of erectile function domain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correction of prothrombin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The Drug Abuse Screening Test 10 (DAST-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Days Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux disease questionnaire (RDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Event-related brain potentials (ERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Children's socio-emotional health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tinnitus-severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of NICE classification in histological prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychosocial stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Exercise Mean Pulmonary Artery Pressure (mPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Exercise Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Exercise Maximum Oxygen Uptake (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Stress Cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of surface roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Inflation Volume of the Silicone Expander
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lesion progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: World Health Organisation Quality of Life (WHOQOL Bref)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hamilton Depression Scale (HAMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of PillCam COLON 2 Capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of medical referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in the area of secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dyspnoea - mMRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnoea - NCSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in dyspnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Methylation profile of DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MicroRNAs profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Implant Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients With Implant Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients With Incisional Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and characteristics of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum CM-101 plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination rate constant (λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life (T½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tricuspid Regurgitation Flow Velocity (TRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain Natriuretic Peptide (BNP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of patients pain free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with at least 50% reduction in vasospastic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability as measured by ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median Change in Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of Systemic Signs Attributable to Candidemia and/or Invasive Candidiasis and Mycological Eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal ultrasound evaluation of the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Bulbar Conjunctival Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Activated area under the curve in ASPI test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest reproducibility of myocardial uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Response (Success of Initial PONV Treatment)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of neoantigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of peptides synthesized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Production time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of consent to tissue acquisition phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects eligible for the treatment phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relapse of a major depressive episode
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: success of the ART restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilation-perfusion ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of Post-ERCP Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change of triglyceride (TG) level in drained fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects reporting solicited local adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting solicited general AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Peak Inspiratory Capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Average Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delivery of comprehensive mammography services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Appropriate follow-up for women
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Circulating Gastric Inhibitory Polypeptide (GIP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Circulating Ghrelin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Circulating Peptide Tyrosine Tyrosine (PYY) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Score of Patient Health Questionnaire-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-prandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Concentration (Cmax) of LY2409021
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve From Time Zero to Infinity (AUC 0-∞) of LY2409021
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival Rate: All Participants
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Rate: Type of First Line TKI
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Rate: Type of Second Line TKI
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Rate: Per Sequence of Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of the diagnostic model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of signs and symptoms of temporomandibular disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Hematologic or GI Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Body contour improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate changes since baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PR interval changes since baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QRS duration changes since baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT interval changes since baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTcF changes since baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anidulafungin area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum NSE level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Neurological Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine Sulfatides Quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Cue Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vaginal Delivery
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of LARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of severe bronchial hyperresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in 24 hour ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-month Progression Free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Intra-patient variation of the choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Focus group interview completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiac kinetic energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urethral patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Optimal Arterial Waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase of global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fentanyl maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative relative abundance of immunotherapy-responsiveness associated species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sustained response defined as HBV DNA persistently ≤ 200 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of COVA™+ CARD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in microbial population of the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients utilizing ovarian tissue
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Age at which patients utilize ovarian tissue
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients electing to have OTC
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-Regional Pro Adrenomedullin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic syndrome diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUROC curve for perfusion index to predict hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma concentrations of choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Score Wanting to olfactory stimuli
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Anxiety Rating Scale (ham-a)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: N1 latency of somatosensory evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: N1P1 amplitude of somatosensory evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: motor threshold of motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: map size of motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrent rate of IgG4-RD
Endpoint domain: Mortality/survival
Primary endpoint: Microbiological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment efficacy
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Exit site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Seated Trough Cuff Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective effects of PTI-801
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of HVPG (hepatic venous pressure gradient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to successfully complete surgical cricothyroidotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Antibody Response to Hepatitis B Surface Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endogenous Thrombin Potential (ETP, nM.min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pregnancies affected by severe early onset FGR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in Immuno globuline E (IgE)-blocking factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of treatment-related neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-time Curve of BI 1265162 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial artery dilator responsiveness to shear stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: late lumen loss in-lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin B12 absorption (increase in holotranscobalamin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Function of the neo-rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of gad-enhancing lesions in T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of lesions in T1 and new lesions in T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Experiencing Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Coefficient of correlation in baroreflex sensitivity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascular function assessed by Flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumour response monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HIV testing rates among partners
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ocular Tear film Mucin MUC5ac concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular tear film Mucin MUC2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic hypoglycemia (diurnal and nocturnal)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in sodium fluorescein corneal staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin infection detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acceptance of LGBT
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area under the concentration-time curve (AUC0-inf) for whole blood concentration of RDC5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: live-birth rate (LBR)
Endpoint domain: Mortality/survival
Primary endpoint: Epigenetic marks in abdominal vs gluteal subcutaneous adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: new neurological deficit
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of other adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of post-operative acute respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes